Identifying genotype-dependent efficacy of single and combined PI3K- and 
MAPK-pathway inhibition in cancer

Sos, Martin L.; Fischer, Stefanie; Ullrich, Roland; Peifer, Martin; Heuckmann, Johannes M.; Koker, Mirjam; Heynck, Stefanie; Stueckrath, Isabel; Weiss, Jonathan; Fischer, Florian; Michel, Kathrin; Goel, Aviva; Regales, Lucia; Politi, Katerina A.; Perera, Samanthi; Getlik, Matthaeus; Heukamp, Lukas C.; Ansen, Sascha; Zander, Thomas; Beroukhim, Rameen; Kashkar, Hamid; Shokat, Kevan M.; Sellers, William R.; Rauh, Daniel; Orr, Christine; Hoeflich, Klaus P.; Friedman, Lori; Wong, Kwok-Kin; Pao, William; Thomas, Roman K.

doi:10.1073/pnas.0907325106

Lokale TagsFreigabegeschichteDetailsÜbersicht

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., et al. (2009). Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America, 106, 18351-18356. doi:10.1073/pnas.0907325106.

Item is Freigegeben

einblenden: alle ausblenden: alle

Basisdaten

einblenden: ausblenden:

Datensatz-Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D597-7 Versions-Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D598-5

Genre: Zeitschriftenartikel

ausblenden:

Urheber:
Sos, Martin L.¹, Autor
Fischer, Stefanie¹, Autor
Ullrich, Roland², Autor
Peifer, Martin¹, Autor
Heuckmann, Johannes M.¹, Autor
Koker, Mirjam¹, Autor
Heynck, Stefanie¹, Autor
Stueckrath, Isabel¹, Autor
Weiss, Jonathan¹, Autor
Fischer, Florian¹, Autor
Michel, Kathrin¹, Autor
Goel, Aviva³, Autor
Regales, Lucia³, Autor
Politi, Katerina A.³, Autor
Perera, Samanthi³, Autor
Getlik, Matthaeus³, Autor
Heukamp, Lukas C.³, Autor
Ansen, Sascha³, Autor
Zander, Thomas², Autor
Beroukhim, Rameen³, Autor
Kashkar, Hamid³, AutorShokat, Kevan M.³, AutorSellers, William R.³, AutorRauh, Daniel³, AutorOrr, Christine³, AutorHoeflich, Klaus P.³, AutorFriedman, Lori³, AutorWong, Kwok-Kin³, AutorPao, William³, AutorThomas, Roman K.¹, Autor          mehr..

Affiliations:
1Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656
2Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663
31. Univ Cologne, Fac Med, D-50931 Cologne, Germany 2. Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA 3. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA 4. Max Planck Soc, Chem Genom Ctr, D-44227 Dortmund, Germany 5. Univ Hosp Bonn Med Sch, Dept Pathol, D-53127 Bonn, Germany 6. Univ Cologne, Fac Med, Dept Internal Med, D-50924 Cologne, Germany 7. Univ Cologne, Fac Med, Ctr Integrated Oncol Cologne Bonn, D-50924 Cologne, Germany 8. Univ Cologne, Fac Med, Inst Med Microbiol Immunol & Hyg, D-50924 Cologne, Germany 9. Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA 02141 USA 10. Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA 11. Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA 12. Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA 13. Novartis Inst BioMed Res, Cambridge, MA 02139 USA 14. Genentech Inc, Dept Canc Signaling & Translat Oncol, San Francisco, CA 94070 USA 15. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA 16. Harvard Univ, Sch Med, Boston, MA 02115 USA 17. Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA, ou_persistent22